- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.03. | AlzeCure Pharma: AlzeCure Achieves Last Patient Last Visit in its Phase II Clinical Trial of the Non-Opioid ACD440 in Neuropathic Pain | 351 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / March 13, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) a pharmaceutical company that develops a broad portfolio of drug candidates... ► Artikel lesen | |
| 07.03. | AlzeCure Pharma: AlzeCure Participates at Redeye Alzheimer Seminar on March 15 | 1.078 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / March 7, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule... ► Artikel lesen | |
| 24.02. | AlzeCure Pharma: AlzeCure Publishes its Year-end Report for January - September 2022 | 362 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / February 24, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its Year-end report for the period January -... ► Artikel lesen | |
| 31.01. | AlzeCure's neuropathic pain candidate study reaches crucial phase | 1 | PharmaTimes | ||
| ALZECURE PHARMA Aktie jetzt für 0€ handeln | |||||
| 31.01. | AlzeCure Pharma: Last Patient Included in Alzecure's Phase II Clinical Trial in Peripheral Neuropathic Pain with The Non-Opioid ACD440 | 271 | ACCESSWIRE | STOCKHOLM, SE / ACCESSWIRE / January 31, 2023 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR) a pharmaceutical company that develops a broad portfolio of drug candidates... ► Artikel lesen | |
| 12.01. | Nasdaq Stockholm AB: Last day of trading in paid subscription shares (BTA) of AlzeCure Pharma AB (22/23) | 289 | GlobeNewswire | Trading in AlzeCure Pharma AB paid subscription shares is to cease. The last
trading day is January 12, 2023.
Short name: ALZCUR BTA
---------------------------
ISIN code: SE0019174087
---------------------------
Orderbook... ► Artikel lesen | |
| 11.01. | AlzeCure begins Alzheimer's therapy development phase | 1 | PharmaTimes | ||
| 11.01. | AlzeCure Pharma: AlzeCure Selects CD and Enters Next Development Phase with Alzstatin ACD680 Against Alzheimer's | 595 | ACCESSWIRE | STOCKHOLM, SE / ACCESSWIRE / January 11, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule... ► Artikel lesen | |
| 28.12.22 | AlzeCure Pharma: First Day of Trading in BTA 2 | 265 | ACCESSWIRE | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO RUSSIA, BELARUS, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, UNITED STATES... ► Artikel lesen | |
| 27.12.22 | Nasdaq Stockholm AB: Listing of paid subscription shares of AlzeCure Pharma AB (698/22) | 327 | GlobeNewswire | With effect from December 28, 2022, the paid subscription shares in AlzeCure
Pharma AB will be traded on First North Premier Growth Market. Trading will
continue until further notice.
Instrument:... ► Artikel lesen | |
| 21.12.22 | AlzeCure's promising Alzheimer's abstract accepted | 6 | PharmaTimes | ||
| 20.12.22 | AlzeCure Pharma: AlzeCure gets Abstract Accepted on New Potential Disease-Modifying Effects of ACD856 Against Alzheimer's | 320 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / December 20, 2022 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small... ► Artikel lesen | |
| 15.12.22 | AlzeCure Pharma: AlzeCure Gets Late-Breaking Abstract on New Data with Its Alzheimer Project Alzstatin Accepted At AD/PD 2023 | 254 | ACCESSWIRE | STOCKHOLM, SE / ACCESSWIRE / December 15, 2022 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule... ► Artikel lesen | |
| 13.12.22 | AlzeCure Pharma AB's Chief Scientific Officer has Participated in an Interview with Erik Penser Bank | 241 | ACCESSWIRE | STOCKHOLM, SE / ACCESSWIRE / December 13, 2022 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) ("AlzeCure" or "the Company"), a pharmaceutical company that develops a broad portfolio... ► Artikel lesen | |
| 06.12.22 | The subscription period in AlzeCure Pharma AB's Rights Issue Begins Today and the CEO has Participated in a Company Presentation and CEO Interview with Erik Penser Bank | 265 | ACCESSWIRE | STOCKHOLM, SE / ACCESSWIRE / December 06, 2022 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) ("AlzeCure" eller "Bolaget"), a pharmaceutical company that develops a broad portfolio... ► Artikel lesen | |
| 02.12.22 | Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of AlzeCure Pharma AB (630/22) | 447 | GlobeNewswire | With effect from December 06, 2022, the subscription rights in AlzeCure Pharma
AB will be traded on First North Premier Growth Market. Trading will continue
up until and including December 15, 2022.... ► Artikel lesen | |
| 01.12.22 | AlzeCure Pharma: New Data on Alzstatin for Preventive Treatment Against Alzheimer's Presented at Alzheimer's Conference CTAD | 295 | ACCESSWIRE | STOCKHOLM, SE / ACCESSWIRE / December 01, 2022 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule... ► Artikel lesen | |
| 30.11.22 | AlzeCure Pharma: New Data Strengthening the Continued Clinical Development of NeuroRestore ACD856 Presented at Alzheimer's Conference | 381 | ACCESSWIRE | STOCKHOLM, SE / ACCESSWIRE / November 30, 2022 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule... ► Artikel lesen | |
| 30.11.22 | XFRA CAPITAL ADJUSTMENT INFORMATION - 30.11.2022 | 568 | Xetra Newsboard | Das Instrument CB5 US2005251036 COMMERCE BANCSHS INC. DL5 EQUITY wird cum Kapitalmassnahme gehandelt am 30.11.2022 und ex Kapitalmassnahme am 01.12.2022 The instrument CB5 US2005251036 COMMERCE BANCSHS... ► Artikel lesen | |
| 14.11.22 | AlzeCure Pharma: AlzeCure Presents at Aktiespararna and Carlsquare | 284 | ACCESSWIRE | STOCKHOLM, SE / ACCESSWIRE / November 14, 2022 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates... ► Artikel lesen |
Seite:
1 2 3 Weiter >>
52 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS | 275,50 | +0,49 % | Aktienmarkt: Kurs der Vertex Pharmaceuticals-Aktie im Plus | Im Plus liegt aktuell die Vertex Pharmaceuticals-Aktie . Der jüngste Kurs betrug 296,24 US-Dollar. Am US-amerikanischen Aktienmarkt hat sich heute der Anteilsschein von Vertex Pharmaceuticals zwischenzeitlich... ► Artikel lesen | |
| VIATRIS | 8,700 | +0,20 % | Merck, Viatris close in on settlement in long-running Januvia patent case | ||
| OPKO HEALTH | 1,216 | +0,35 % | Aktien New York: Dow nach Kursrutsch vom Vortag etwas unter Druck | NEW YORK (dpa-AFX) - An der Wall Street hat der Leitindex Dow Jones Industrial nach seinem Kursrutsch am Vortag etwas weiter nachgegeben. Der US-Leitindex fiel am Mittwoch um 0,48 Prozent auf 32 698... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 1,215 | +6,02 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update | Phase 3 REGAL GPS AML Study on Track for Interim Analysis by Late 2023/Early 2024 Ongoing Phase 1 Study of CDK9 Inhibitor Suggests Broad Therapeutic Window and High Potential for Both Monotherapy and... ► Artikel lesen | |
| ALTIMMUNE | 3,793 | -2,31 % | Altimmune hits 10-month low as Goldman Sachs downgrades on weight loss data | ||
| JAGUAR HEALTH | 0,750 | -0,66 % | Jaguar Health, Inc.: Jaguar Health to Hold Investor Webcast Monday, March 27th at 8:30 AM EDT Regarding Q4 2022 Financials & Corporate Updates | Click here to register for webcastCompany plans to file its Annual Report on March 24, 2023 on Form 10-K for the fiscal year ended December 31, 2022SAN FRANCISCO, CA / ACCESSWIRE / March 21, 2023 /... ► Artikel lesen | |
| SPECTRUM PHARMACEUTICALS | 0,674 | +0,45 % | SPECTRUM PHARMACEUTICALS INC - 8-K, Current Report | ||
| ADAMIS PHARMACEUTICALS | 0,105 | -4,63 % | Adamis Pharmaceuticals GAAP EPS of -$0.18, revenue of $4.75M | ||
| ZYNERBA PHARMACEUTICALS | 0,400 | -2,68 % | Zynerba Pharmaceuticals, Inc.: Zynerba Pharmaceuticals Confirms Not Holding Cash Deposits or Securities at Silicon Valley Bank | DEVON, Pa., March 13, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 7,938 | 0,00 % | Aurinia Reports Fourth Quarter and Full Year 2022 Financial Results and Company Updates | VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the fourth quarter and the full year ended... ► Artikel lesen | |
| KIORA PHARMACEUTICALS | 3,360 | +9,09 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Announces the Acceptance of Three Abstracts at the 2023 ARVO Annual Meeting | Encinitas, California--(Newsfile Corp. - March 10, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced three abstract acceptances for oral and poster presentation... ► Artikel lesen | |
| PHOTOCURE | 5,050 | -7,08 % | Photocure provides update on Karl Storz's commitment to maximize the commercial adoption of Saphira and decision to discontinue flexible BLC tower production in the U.S. | ||
| LIPOCINE | 0,270 | -2,52 % | Lipocine Inc.: Lipocine Announces Financial Results for the Year Ended December 31, 2022 | SALT LAKE CITY, March 10, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") disorders by leveraging its proprietary... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 7,132 | -5,21 % | XFRA 8AT: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILACLARIS THERAPEUTICS... ► Artikel lesen | |
| SOLID BIOSCIENCES | 3,780 | +3,85 % | Solid Biosciences Inc.: Solid Biosciences to Participate at BMO Biopharma Spotlight Series: Genetic Medicine Delivery |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
